<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159881">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063594</url>
  </required_header>
  <id_info>
    <org_study_id>MARV2013-CP-001</org_study_id>
    <nct_id>NCT02063594</nct_id>
  </id_info>
  <brief_title>Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers</brief_title>
  <official_title>Phase 1 Single Dose, Double-blind, Dose-escalation, Safety, Tolerability and Pharmacokinetic Study of NCTX (PEGylated Liposomal Iodixanol Injection) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marval Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marval Pharma Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, single dose, dose-escalation study to evaluate the
      safety, tolerability, and pharmacokinetics of NCTX (PEGylated Liposomal Iodixanol Injection)
      administered intravenously to healthy volunteers. In addition, computed tomography (CT)
      scans will be acquired to measure radiographic density in regions of interest (ROI) at times
      from 3-5 hours and up to 72 hours following NCTX administration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Assessment of safety by clinical laboratory parameters, vital sign measurements, electrocardiograms, and adverse event monitoring</measure>
    <time_frame>Baseline and up to and including 28 days post drug administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum blood concentration (Cmax), half-life (t1/2), and  ratio of free to encapsulated circulating iodixanol</measure>
    <time_frame>Baseline and up to 28 days post drug administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic density in ROIs by abdominal CT imaging</measure>
    <time_frame>From 3-5 hours and up to 72 hours following NCTX administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 of 8 subjects in each dose cohort will receive normal saline as a single intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NCTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 of 8 subjects in each dose cohort will receive NCTX (PEGylated Liposomal Iodixanol Injection) as a single intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NCTX (PEGylated Liposomal Iodixanol Injection)</intervention_name>
    <description>Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg</description>
    <arm_group_label>NCTX</arm_group_label>
    <other_name>NCTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug</description>
    <arm_group_label>Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, nonsmoking men and women 18 to 55 years of age

          -  Body Mass Index (BMI) between 18.5 and 30.0 kg/m2

          -  Serum creatinine within normal range and calculated creatinine clearance of 80
             mL/min/1.73 m2 or greater

        Exclusion Criteria:

          -  Concurrent enrollment in another clinical trial or treatment with any investigational
             products or therapies within 30 days prior to dosing

          -  History of infusion reactions to liposomes, nanoparticles, monoclonal antibodies, or
             intravenously administered materials

          -  History of allergic/anaphylactoid-like reactions attributed to iodinated contrast
             agents or other components of the formulation

          -  Disturbances in normal fat metabolism, or total cholesterol greater than 240 mg/dL

          -  Pregnant or nursing women

          -  Exposure to significant radiation within 1 year, or previous CT scan within 5 years
             prior to check-in
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip T Leese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Phase 1 Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen MacLeod</last_name>
    <phone>207-452-2039</phone>
    <email>karen.macleod@marvalpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quintiles Phase 1 Services</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philip Leese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iodixanol</keyword>
  <keyword>Iodinated Contrast</keyword>
  <keyword>Liposome</keyword>
  <keyword>Computed Tomography</keyword>
  <keyword>X-ray Imaging</keyword>
  <keyword>Blood pool agent</keyword>
  <keyword>Biomarker</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
